OSE Immunotherapeutics - Full Lusvertikimab results reflect potential in UC
OSE Immunotherapeutics’ final analysis of the CoTikiS trial in ulcerative colitis (UC) confirmed that Lusvertikimab met the primary endpoint with...
116 Views
VietNam Holding - First redemption tender a success
VietNam Holding (VNH) delivered a 27.3% net asset value (NAV) per share total return over the last 12 months (ending 31 October) in sterling terms....
33 Views
Murray Income Trust - Income focus keeps paying dividends
Murray Income Trust (MUT) invests in high-quality, mainly UK-listed stocks. MUT’s manager, Charles Luke, believes quality stocks are best placed to...
143 Views
HELLENiQ ENERGY - Margins troughed in Q3, expect Q4 improvement
HELLENiQ ENERGY’s Q324 results were held back by a weak refining environment, as previously guided by the company, but showed an impressive...
148 Views
Solid State - Defence contract delay affects expectations
The delay of a major contract inevitably has an impact on short-term profitability. Solid State has a strong balance sheet and a growth strategy to...
129 Views